Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by First Trust Advisors LP

First Trust Advisors LP trimmed its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 41.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 23,169 shares of the company’s stock after selling 16,242 shares during the period. First Trust Advisors LP owned 0.08% of Krystal Biotech worth $3,630,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of the business. US Bancorp DE lifted its stake in Krystal Biotech by 8.7% during the fourth quarter. US Bancorp DE now owns 1,027 shares of the company’s stock worth $161,000 after purchasing an additional 82 shares during the last quarter. Summit Investment Advisors Inc. grew its position in shares of Krystal Biotech by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 2,595 shares of the company’s stock valued at $407,000 after buying an additional 82 shares during the last quarter. Crossmark Global Holdings Inc. raised its stake in Krystal Biotech by 5.5% during the 4th quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company’s stock worth $362,000 after acquiring an additional 121 shares in the last quarter. Envestnet Asset Management Inc. lifted its position in Krystal Biotech by 1.1% in the fourth quarter. Envestnet Asset Management Inc. now owns 11,630 shares of the company’s stock valued at $1,822,000 after acquiring an additional 121 shares during the last quarter. Finally, Perigon Wealth Management LLC boosted its stake in Krystal Biotech by 1.5% in the fourth quarter. Perigon Wealth Management LLC now owns 8,289 shares of the company’s stock valued at $1,200,000 after acquiring an additional 123 shares in the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Price Performance

Krystal Biotech stock opened at $166.16 on Friday. The stock’s 50 day moving average price is $174.92 and its 200 day moving average price is $171.30. Krystal Biotech, Inc. has a 1-year low of $141.72 and a 1-year high of $219.34. The company has a market cap of $4.80 billion, a PE ratio of 55.57 and a beta of 0.75.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping analysts’ consensus estimates of $1.29 by $0.23. The business had revenue of $91.10 million for the quarter, compared to analysts’ expectations of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business’s revenue for the quarter was up 116.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.30 EPS. On average, equities research analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the sale, the insider now directly owns 1,463,711 shares of the company’s stock, valued at approximately $260,233,178.69. This represents a 1.68 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the transaction, the chief accounting officer now owns 12,604 shares of the company’s stock, valued at approximately $2,208,472.88. The trade was a 5.62 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 13.70% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on KRYS. HC Wainwright lifted their price target on Krystal Biotech from $221.00 to $240.00 and gave the stock a “buy” rating in a research report on Monday, April 28th. Chardan Capital increased their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th. Jefferies Financial Group initiated coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They issued a “buy” rating and a $245.00 price objective on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Krystal Biotech in a report on Thursday, February 20th. Finally, Citigroup upped their price objective on Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research note on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $222.71.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).